TORRENT PHARMACEUTICALS
BSE ticker code |
500420 |
NSE ticker code |
TORNTPHARM |
Major activity |
Pharmaceuticals |
Managing Director |
Samir Mehta |
Equity capital |
Rs. 84.62 crore; FV Rs. 05 |
52 week high/low |
Rs. 3305 / Rs. 2485 |
CMP |
Rs. 2890.00 |
Market Capitalisation |
Rs. 48905.37 crore |
Recommendation |
Accumulate at declines |
Pole player in domestic branded medicines
Torrent Pharmaceuticals is one of the country’s leading pharmaceutical companies, being
the eighth largest in
India. It ranks among the top 5 players in the country in cardiac, central nervous
system (CNS), vitamins, minerals and
nutrients (VMN) and gastro-intestinal therapeutic areas. Despite the pandemic, its
financial performance is quite remarkable. What is more, its future prospects are all
the more promising
Consider:
-
The company stands in a
strong position in the country’s pharmaceutical industry. It has 10 brands
above Rs 100 crore. Its domestic business franchise has chronic and subchronic
therapeutic segments which
contribute around 73 per cent of the
India business and which have an
operating margin of more than 30 per
cent. The company has 70 brands
which are leaders in their respective
markets. The largest therapy is cardiac, which contributes 31 per cent of
domestic revenues, followed by GI, CNS and vitamins at 16%
and 15% respectively. The management gives a lot of emphasis on research and
development, with R&D spend accounting for around 5 to 7 per cent of sales.
-
The company is doing quite well on the export front.
Today it has a presence in 40 countries and derives almost
55 per cent of its revenues from exports, mainly from the US,
Europe, Brazil and the Philippines. The company was facing
regulatory challenges and its revenue growth was under stress
on account of compliance issues of the Dahej and Indrad
facilities with the US FDA. As the company has already submitted CAPA
(corrective and preventive action), the problem
has been sorted out and the company’s business in the US is
on the rise. Meanwhile, the company’s European business is
mainly in Germany and the UK where it has a direct presence. Germany – the
largest market in western Europe — is
the 4th largest global market in the world. Torrent is the number one player
among Indian companies in the German market. Of late, the German business
contributes around 12 to
13 per cent of Torrent’s total revenues. As a strategic move,
Torrent acquired Heumann Pharma GmbS and Co in 2005.
-
Another promising country for Torrent is Brazil,
where Torrent is the largest Indian company and contributes
around 9 per cent of total sales. Torrent has nine pending
filings with ANVISA and has a development basket of around 20 products.
Prospects for the company are highly
encouraging in Germany and Brazil.
Torrent plans to gain marketshare
through introducing speciality focus,
enhancing field force productivity and
introducing new products. Currently,
the company has commercialized 23
branded generics and 20 generic
products. In its branded generic portfolio, the company has 9 filings under
approval, 23 under preparation for
filing in existing business and 19 in
new business. The company expects 3 to 4 products launches
per year from its own portfolio. Licensing opportunities would
provide further growth opportunities in Brazil.
-
The company has expanded its business operations
through the inorganic route. In 2014, it acquired the branded
formulation business of Elder Pharma in India and Nepal for
Rs 2,000 crore. As a result, about 30 brands were added to
Torrent’s portfolio, which included popular brands like Shelcal,
Chymural, and Carnisure. Three years later in 2017, the company acquired the
branded business of Unichem Laboratories
for India and Nepal at a cost of around Rs 3,000 crore. Both
these acquisitions gave a big boost to the topline as well as
bottomline of Torrent.
-
The company is successfully deleveraging its balance sheet by bringing down the
debt burden. Needless to
say, the interest burden, as a result, was reduced from Rs 481
crore in fiscal 2019 to Rs 236 crore in fiscal 2022, and this is
expected to go down further.
The company’s share price is currently quoted around Rs 617 and is sure
to give good returns to investors in due
course.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
7672.80
|
683.10
|
40.40
|
340.0
|
299.80
|
14.60
|
2019-20
|
7939.30
|
999.50
|
59.10
|
640.0
|
285.00
|
20.90
|
2020-21
|
8004.80
|
1239.10
|
73.20
|
700.0
|
344.90
|
23.30
|
2021-22
|
8508.00
|
1084.38
|
64.10
|
960.0
|
351.80
|
23.25
|
BCL INDUSTRIES AND INFRASTRUCTURE
BSE ticker code |
524332 |
NSE ticker code |
BCLIND |
Major activity |
Edible Oils |
Chairman |
R.C. Nayyar |
Equity capital |
Rs. 24.15 crore; FV Rs. 10 |
52 week high/low |
Rs. 525 / Rs. 183 |
CMP |
Rs. 372.05 |
Market Capitalisation |
Rs. 898.50 crore |
Recommendation |
Buy at declines |
Sales triple in last five years
BCL Industries and Infrastructure Ltd, a Mittal
group company, is one of the largest agro-based companies in North India. This
vertically integrated company is engaged in the manufacture of edible oils,
including soyabean oil, sunflower oil, cottonseed oil
and rice bran oil, under the brand
name ‘Homecook’. It also manufactures Vanaspati under the
brand name ‘Do Khajoor’
BCL is also engaged in the
grain-based distillery business. In
fact, it is the only company, not
only in India but also in the entire south Asian region, that has
a forward and backward integrated distillery-ethanol plant.
The company has a unique expertise in producing ENA ethanol from multiple crops. It is
going from strength to
strength and its future prospects are all the more exciting.
Consider:
-
The company has been in expansion mode ever
since its inception in 1976 when it was incorporated as
Bhatinda Chemicals Ltd. In 1991-92, it set up a new
solvent extraction plant of 150/200 tpd capacity and a
Vanaspati plant of 25 tpd. After a year, it increased the
production capacity to 15,000 tpd. In 2001-2002, this
capacity was doubled to 30,000 tpd. As ‘Do Khajoor’
became more and more popular, the company’s topline
as well as bottomline started going up.
-
BCL has developed expertise in producing ENA
ethanol from multiple crops. This allows it to reduce
dependency on a single crop and avoid the vagaries of
raw material price fluctuations. The company has already set up a plant at
Bhatinda of 200 klpd capacity
and is now setting up another plant nearby with the
same capacity. At the same time, its subsidiary, Savak
Sha Distillery, has also set up an ethanol plant with a capacity of 200 klpd.
The plant has been set up with
the help of internal accruals and without raising any
debt. The subsidiary has also got an approval to set up
another ethanol plant with a capacity of 100 klpd at
the same premises. This plant is being set up at minimal capex due to the
existing
facilities. With this 100 klpd
plant going into production by
the end of fiscal 2023, the
company’s total ethanol capacity will go up to 700 klpd – taking into account
the 400 klpd
capacity of the main plant and
the 300 klpd capacity of the
subsidiary. This will make BCL
one of the largest producers of
ethanol from grains in the private sector in India
-
The company has emerged as one of the leading manufacturers of high-quality
rice bran oil in the
world. In 2007-08, it set up a deodorizing system to
achieve an excellent quality of rice bran refined oil.
Little wonder that the company received the BK
Goenka SEA award for refined rice bran oil twice!
-
Needless to say, the growing business of the
company is well reflected in its financial growth. During the last six years,
its sales turnover has expanded
from Rs 642 crore in fiscal 2017 to Rs 1,988 crore in
fiscal 2022, with operating profit advancing from Rs
37 crore to Rs 138 crore and the profit at net level
inching up from Rs 10 crore to Rs 85 crore during
this period. BCL’s financial position has been getting
stronger and stronger by the day, with reserves at the
end of March 2022 standing at Rs 261 crore against
an equity capital of Rs 27 crore, that too after a 1:1
bonus issue in 1992. The company has been regularly paying dividends, the rate
for the last year being
50 per cent.
Prospects for the
company going ahead
are all the more promising and this will be a
very good addition to
the portfolios of longterm investors.
CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
890.50
|
41.30
|
21.60
|
12.0
|
107.70
|
26.30
|
2019-20
|
918.32
|
26.00
|
13.59
|
--
|
112.40
|
29.80
|
2020-21
|
1427.20
|
41.80
|
17.30
|
50.0
|
117.70
|
16.70
|
2021-22
|
1987.74
|
84.84
|
35.10
|
50.0
|
151.60
|
16.68
|
VISAKA INDUSTRIES
BSE ticker code |
509055 |
NSE ticker code |
VISAKAIND |
Major activity |
Cement & Cement Products |
Managing Director |
Dr. G. Vivekanand |
Equity capital |
Rs. 17.28 ; FV Rs. 10 |
52 week high/low |
Rs. 874 / Rs. 490 |
CMP |
Rs. 516.25 |
Market Capitalisation |
Rs. 892.13 crore |
Recommendation |
Buy at declines |
At forefront of building products
The second largest cement asbestos product manufacturer in India, Visaka Industries has
multiple products — from
cement sheets and fibre cement boards to hybrid solar roofs
and fibre yarn. Since its inception in 1981, the company has
remained at the forefront, developing sustainable products
and meeting demands from domestic as well as international
markets. The company has been
growing steadily and its future prospects seem to be all the more promising.
Consider:
-
The Hyderabad-based
company employs a unique business model for its product segment.
Its asbestos cement sheet (ACS)
finds extensive usage in urban and
semi-urban interiors while cement
asbestos products like V-boards and
panels largely address rural markets,
allowing for adequate geographic
de-risking. The company’s customers for V-panels and boards
include the GMR group, Shapoorji Pallonji, Soma Enterprises, TCS, Gujarat Ambuja, the Eanadu group, Uranium
Corporation of India and Larsen&Toubro. Its building products are marketed directly to retailers, eliminating the conventional company-distributor-retailer model and resulting in
a better marketplace understanding. As a result, the company
enjoys an enduring relationship with an extensive network of
agents and retailers.
-
Visaka has emerged as a credible, passionate and
innovative solution provider. With its transformed product
portfolio under V-next, the company enables contractors,
builders, architects and applicators to emphasise sustainable
architecture and build the future. The company’s V-next
boards are designed to provide strength and stability as well
as aesthetic solutions. V-next premium planks, a speciality
grade product from Visaka, have become the choice of many
consultants, engineers, builders and contractors and have
been tested to survive even in extreme outdoor applications. In short, demand for the company’s products is constantly on
the rise.
-
The company also manufactures and is a global
supplier of the wonder yarn – a human-made spool for various fabric applications across garments, apparels, furnishings, automotive fabrics and other technical textiles. The company is famed for roofing the largest
Muratec Twin jet spun yarn technology facility with its world-class
manufacturing set-up.
-
With a view to addressing energy demands
sustainability, the company has
launched a path-breaking hybrid
rooftop solar product called ATUM
– the first of its kind in India. With
its superior technological capabilities, ATUM is thermally efficient and
generates 20% more revenue when
compared to conventional solar panels. ATUM is the only renewable energy solution that is both a roof and solar panel
designed to meet consistent energy demands that one can
manage on his/her smartphone.
-
With 12 manufacturing facilities, 13 marketing offices and a pan-India distribution channel of over 7,000 dealer
outlets, Visaka has emerged as a sustainable business enterprise and a Green Pro Certified Organisation. Its excellent
corporate governance and professional management have kept
Visaka on a steady growth path.
-
All these factors have quickened the pace of growth
of the company on the financial front. During the last six years,
the company’s sales turnover has expanded from Rs 967 crore
in fiscal 2017 to Rs 1,416 crore, with the profit at net level
taking a high jump from Rs 44.45 crore to Rs 118.53 crore
during this period. The company’s financial position is very
strong, with reserves at the end of March 2022 standing at Rs
715 crore – over 41 times its equity capital of Rs 17.28 crore.
The company is deleveraging its balance sheet by reducing
debt. The interest burden as a result has
gone down from Rs 20 crore in fiscal 2019
to Rs 11.56 crore in fiscal 2022. and in the
very near future Visaka will be a totally debtfree company.
This is a stock worth investing in, and
discerning investors should include it in their
portfolios.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Series
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
1136.40
|
67.60
|
42.60
|
70.0
|
314.50
|
14.30
|
2019-20
|
1050.40
|
49.10
|
30.90
|
150.0
|
318.00
|
9.80
|
2020-21
|
1146.50
|
110.60
|
67.10
|
150.0
|
377.40
|
19.60
|
2021-22
|
1415.81
|
118.09
|
68.30
|
150.0
|
423.60
|
17.44
|